Wegovy pill reaches one million US users as Novo Nordisk raises 2026 outlook
Novo Nordisk’s Wegovy pill surpasses one million US users since January launch as company raises 2026 outlook amid rising competition and patent pressures
Novo Nordisk said its Wegovy pill has been taken by more than one million people in the United States since the product launched in January, a milestone the company cited as justification for a slightly improved 2026 outlook. The increased confidence follows more than two million prescriptions written for the oral semaglutide formulation and a boost in investor sentiment after the quarter ended. Company executives framed the uptake as the strongest start for a GLP 1 based product in the US to date.
Uptake and early demand in the US
The company reported that prescriptions for the Wegovy pill exceeded two million during the initial months of availability and that nearly 80 percent of pill users were new to GLP 1 therapy. Executives said the pill has drawn patients who had not previously used injectable GLP 1 drugs and has prompted some switching from competitor products. Novo Nordisk presented the figures as evidence that the oral format is expanding the market beyond existing treatment populations.
Quarterly results show mixed performance
Despite the pill s early momentum, Novo Nordisk posted a decline in adjusted revenue for the first quarter with currency adjusted sales down four percent to 70.1 billion Danish kroner. Operating profit fell six percent on a currency adjusted basis to 32.86 billion kroner, leaving investors and analysts focused on when the company might resume growth. Management said the Wegovy pill offsets some headwinds but is not an immediate remedy for a period of margin pressure.
Guidance revised and shares react
Novo Nordisk narrowed its expected 2026 currency adjusted revenue and profit decline to between four and twelve percent from a previous range of five to thirteen percent. Markets reacted positively to the revision and the company s statements about uptake of the Wegovy pill, with the share price rising as investors reevaluated the outlook. Fund managers noted the guidance shift but cautioned that structural pressures remain that could limit the speed of recovery.
Competitive landscape and patent timelines
The GLP 1 category is facing new entrants and downward pricing pressure that have affected margins in the US market. Rival companies have introduced competing oral and injectable therapies, and US rebate dynamics continue to squeeze returns for manufacturers. Novo Nordisk also faces a staggered patent expiry schedule with semaglutide protections already lapsed in some jurisdictions and scheduled to lapse in Europe and the United States in 2031, a factor that industry watchers say will accelerate competition over the coming years.
Product mix and clinical differentiation
Novo Nordisk has sought to protect market position through product innovation and dosage variation across formats. The company introduced a higher dose Wegovy injection that produced larger weight loss in trials, and it says the pill has shown strong tolerability and effectiveness in people with obesity. Competitors, including companies with tirzepatide based therapies, have retained leading efficacy in certain injectable regimens, creating a segmented market where oral convenience and injectable potency coexist.
Pipeline prospects and strategic bets
Executives highlighted next generation candidates as crucial for long term performance with particular emphasis on a dual acting compound known as Zenagamtide. The drug targets both GLP 1 and amylin pathways and has shown encouraging early data, leading investors to regard it as a potential successor to current leaders. Novo Nordisk also experienced setbacks with other candidates in head to head comparisons, underscoring the high stakes of late stage development and the importance of regulatory approvals.
Novo Nordisk said it expects further regulatory advances for its pipeline this year and signaled plans to roll out the Wegovy pill in additional markets before year end, though it declined to specify countries. Analysts and fund managers said the combination of an expanding oral offering and next generation therapies will determine whether the company can regain sustained growth in a more crowded obesity treatment market.
Investor and patient demand for GLP 1 based therapies continues to reshape the pharmaceutical landscape as companies race to diversify delivery formats and broaden patient access. The Wegovy pill s milestone in the United States marks a significant commercial achievement for Novo Nordisk, but the company faces ongoing pricing pressures, patent cliffs and fierce competition that will shape performance in 2026 and beyond.
